


Maxime Laugeois, Brice Hoffmann, Paul Join-Lambert, Anna Kriukova, Maud Jusot, Ennys Gheyouché, Stéphanie Labouille, Juan Sanz García, Christopher Housseman, Nicolas Brosse, Clarisse Descamps, Guillaume Plum, Nicolas Drizard, Cédric Thao, Hamza Tajmouati, Brian Atwood, Nicolas Do Huu, Quentin Perron, Yann Gaston-Mathé


Iktos SAS (65 Rue de Prony, 75017 Paris, France) & Iktos Inc (50 Milk Street, Boston MA 02109)

BACKGROUND

- Hit discovery is a crucial step in the drug discovery process, identifying new areas of chemical space for development
- Druglike chemical space is vast (~ 10^{60}); exploration is challenging
- The larger the chemical space to explore within a database, the higher the likelihood of finding hits



Virtual Screening: High throughput docking of chemical libraries; allows for rapid screening of large libraries, significantly reducing time & cost associated with experimental screening



- ☹️ Efficient way to find hits against biological targets
- ☺️ Several success stories reported over the last two decades


- ☹️ Limited by the size of the compound database that can be docked
- ☹️ Until recently, Virtual Screening campaigns typically processed compound databases of available building blocks (~ 10^5 - 10^6)
- ☹️ Ultra-large libraries of make-on-demand building blocks has increased library size (~ 10^8 - 10^{10} and increasing) making Virtual Screening computationally intractable

Therefore, an algorithmically efficient approach to screen large libraries for hit discovery is desirable

IKTOS' SOLUTION: dockAI



Efficiently explore virtual libraries of chemical providers to find new active compounds rapidly and at low cost





dockAI PIPELINE

Docking scores for billions of molecules obtained by docking <1% of data
Pipeline based on Active Learning approach
Parallel docking on the cloud (AWS)
Hits for further analysis in 1-2 days

COMPARISON WITH SCHRÖDINGER

Initial Dataset: D4 Dopamine receptor ($n=140M$)
Active learning iterations: Iktos→35; Schrödinger→5
Results:
• ~75% of hit molecules retrieved after 1M dockings by dockAI
• High diversity; very good coverage of the chemical space
Conclusion: dockAI outperforms Schrödinger's comparable approach*

Data extracted from: *J. Chem. Theory Comput.* 2021, 17, 7106-7119.



dockAI IN COMMERCIAL PROJECTS

Project 1: South-Korean biotech

Objective

- Find druglike hits for a CNS target; X-ray ligands are derived from natural compounds; very few druglike molecules from competitors
- 20 X-ray structures in PDB; resolution 1-3Å

Selection criteria

- Docking score
- Key interactions


$0 < \log P < 5$	$200 < MW < 500$	$QED \geq 0.5$
$RotBonds \leq 5$	$HBA \leq 7$	$HBD \leq 3$

Chemical library size

- WuXi: 100 Million
- Mcule: 160 Million

dockAI protocol

- 5 runs, each with a different setup, changing the reward function or X-ray structure
- Docking runs on Iktos' AWS infrastructure
- 2.7 Million dockings in total



RESULTS

- 62 molecules have been synthesized and tested so far
- 5 different scaffolds in potential hits identified
- 20 molecules <3 μM , up to 10 nM (30% hit rate)

Project 2: Medicines for Malaria Ventures

(in partnership with AWS and Intel)



Objective

- Find druglike hits to target enzyme from Plasmodium; known X-ray ligands are large and flexible molecules
- 3 X-ray structures from literature and 1 proprietary X-ray structure available

Selection criteria

- Docking score
- Key interactions

$0 < \log P < 5$	$200 < MW < 500$	$QED \geq 0.5$
$RotBonds \leq 5$	$HBA \leq 7$	$HBD \leq 3$

Chemical library size


- Enamine REAL: 5.5 Billion
- Compounds cost <250€/2mg

dockAI protocol

- 2 runs, each with different setup, changing the X-ray structure
- 2 million dockings in total, in 1 day
- Docking on AWS, up to 100K dockings in parallel

RESULTS

- 200 molecules representing 20 series
- 176 molecules synthesized in 4 weeks by Enamine
- Initial results indicate ~10 hits (dose response ongoing)



OTHER IKTOS PRODUCTS



Makya is a chemist-friendly SaaS platform for AI-driven *de novo* 2D drug design focused on MPO. Ask us about its features or visit makya.ai



Spaya is an AI-powered platform to discover and prioritize retrosynthetic routes for your molecules. Ask us about its features or visit spaya.ai to get started for free



Visit iktos.ai